Skip to content
Screener

PTC Therapeutics PTCT Q2 2025 earnings

Reported August 7, 2025 · After market close

Revenue$178.9MMiss by $12.6M
EPS-$0.83Beat by $0.24
Revenue estimate$191.5M
EPS estimate-$1.07

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$303.9M
EPS estimate$0.29

Financials

Q2 2025

Income statement

See full
Revenue$178.9M-4.2%
Operating income-$35.0M+13.1%
Net income-$64.8M+34.6%
EPS (diluted)-$0.83+35.7%

Balance sheet

See full
Cash & equivalents$1.0B+55.4%
Total debt$393.5M-1.1%
Total equity-$206.5M+78.9%
Total assets$2.6B+37.5%

Cash flow

See full
CapEx$1.3M—

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$3.93B+68.1%
Enterprise value$3.31B+58.9%
P/E6.3×—
P/S2.2×-0.4×

Profitability

See full
Operating margin40.7%+30.0pp
Net margin35.6%+22.3pp

Returns & leverage

See full
Current ratio3.6×+1.4×

Segments

By product

See full
Translarna$59.5M—
Emflaza$36.4M—
Other Products$10.6M—

By segment

See full
Life Science$178.9M-4.2%

FAQ

When did PTC Therapeutics report Q2 2025 earnings?
PTC Therapeutics (PTCT) reported Q2 2025 earnings on August 7, 2025 after market close.
What were PTC Therapeutics's Q2 2025 revenue and EPS?
PTC Therapeutics reported revenue of $178.9M and eps of $-0.83 for Q2 2025.
Did PTC Therapeutics beat estimates in Q2 2025?
Revenue missed the consensus estimate of $191.5M by $12.6M. EPS beat the consensus estimate of $-1.07 by $0.24.
How did PTC Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 4.2% from $186.7M a year earlier and eps grew 28.4% from $-1.16.
Where can I find PTC Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001558370-25-010786) and the 10-Q periodic report (0001558370-25-010796) directly on SEC EDGAR. The filing index links above go to sec.gov.